Discover how phosphodiesterase-4 (PDE-4) inhibitors manage inflammation in people with mild to severe plaque psoriasis.

PDE inhibitors, in particular the PDE5 (cyclic GMP PDE) inhibitors avanafil, lodenafil, sildenafil, tadalafil, udenafil and vardenafil, are regarded as efficacious, having a fast onset of drug ...

Three new studies support the use of phosphodiesterase-5 inhibitors for the resolution of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by increasing cyclic adenosine monophosphate (cAMP) levels, an important molecule in regulating inflammation.

PDE3 inhibitors are already in clinical use for treating heart failure, thrombosis, asthma, and other conditions, but their potential in promoting bone outgrowth by enhancing CNP signaling ...

Transpire Bio has licensed an inhaled PDE4 inhibitor from China’s Intragrand Pharma as a potential treatment for idiopathic pulmonary fibrosis.

Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition and demonstrated high selectivity over other PDE families.

Cerevel Therapeutics Inc. and Pfizer Inc. have jointly developed azaindole compounds acting as phosphodiesterase 4 (PDE4) inhibitors potentially useful for the treatment of psoriasis, atopic ...

In this study, we attempted to stimulate CNP signaling using PDE inhibitors." Read the full story here.